aTYR PHARMA (ATYR) Capital Expenditures (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Capital Expenditures came in at $73000.0 in Q2 2026, up 711.11% on a YoY basis from $9000.0 in Q2 2025, and down 47.1% quarter-over-quarter from $138000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Capital Expenditures (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Capital Expenditures for 13 consecutive years, with $73000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Capital Expenditures rose 711.11% year-over-year to $73000.0; the trailing twelve-month figure through Jun 2026 stood at $279000.0 (up 469.39% YoY), and the FY2025 full-year result was $77000.0, up 18.46% from the prior year.
- Capital Expenditures slipped to $73000.0 in Q2 2026 per ATYR's latest filing, from $138000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.4 million in Q2 2023 and bottomed at $8000.0 in Q2 2024.
- Historically, Capital Expenditures has averaged $365235.3 across 5 years, with a median of $43000.0 in 2022.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 6116.67% in 2022, then slumped 99.67% in 2024.
- Over 5 years, Capital Expenditures stood at $1.1 million in 2022, then sank by 98.48% to $17000.0 in 2023, then surged by 47.06% to $25000.0 in 2024, then rose by 24.0% to $31000.0 in 2025, then soared by 135.48% to $73000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $73000.0, $138000.0, and $31000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 37.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -1.87 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 73,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 73,000.00 |
| Mar 31, 2026 | 138,000.00 |
| Dec 31, 2025 | 31,000.00 |
| Sep 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | 15,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 17,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 557,000.00 |
| Jun 30, 2023 | 2.40 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 426,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 43,000.00 |
| Dec 31, 2021 | 18,000.00 |
| Sep 30, 2021 | 61,000.00 |
| Jun 30, 2021 | 96,000.00 |